Supplemental Figure 6 from CTLA-4 Limits Anti-CD20–Mediated Tumor Regression

Zhenhua Ren,Jingya Guo,Jing Liao,Yan Luan,Zhida Liu,Zhichen Sun,Xiaojuan Liu,Yong Liang,Hua Peng,Yang-Xin Fu

DOI: https://doi.org/10.1158/1078-0432.22467110.v1

2023-01-01

Abstract:Supplementary Figure 6. The percentage of CTLA4+ CD8+ T cells is much lower than that of CTLA-4+ Treg cells in the large established B-cell lymphoma.

What problem does this paper attempt to address?

Supplemental Figure 1 from CTLA-4 Limits Anti-CD20–Mediated Tumor Regression

Zhenhua Ren,Jingya Guo,Jing Liao,Yan Luan,Zhida Liu,Zhichen Sun,Xiaojuan Liu,Yong Liang,Hua Peng,Yang-Xin Fu

DOI: https://doi.org/10.1158/1078-0432.22467125

2023-01-01

Abstract:Supplementary Figure 1. The therapeutic effect of anti-CD20 is not CD4+ T cell-dependent.
Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Wenqun Zhong,Zebin Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23907869

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia A. Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22494754

2023-01-01

Abstract:IL-6 modulates expression of NK receptor and their ligands in EGFR mutant tumors.
Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia A. Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22494757.v1

2023-01-01

Abstract:EGFR-mutant NSCLC EGFR-independent tumor model is refractory to EGFR-TKI treatment.
Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Ли Шен,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael A. Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22490453.v1

2023-01-01

Abstract:EGFR-mutant NSCLC tumor cells with acquired resistance to an EGFR-TKI display augmented IL-6 gene expression.
CTLA-4 Limits Anti-Cd20-mediated Tumor Regression

Zhenhua Ren,Jingya Guo,Jing Liao,Yan Luan,Zhida Liu,Zhichen Sun,Xiaojuan Liu,Yong Liang,Hua Peng,Yang-Xin Fu

DOI: https://doi.org/10.1158/1078-0432.ccr-16-0040

IF: 13.801

2017-01-01

Clinical Cancer Research

Abstract:Purpose: The inhibition of tumor growth by anti-CD20 antibody (Ab) treatment is mediated by Ab- and complement-dependent cytotoxicity in xenograft tumor models. In addition, anti-CD20 therapy for B-cell lymphoma can result in intrinsic and extrinsic tumor resistance to further Ab treatment. However, adaptive immune response–related resistance has not been well studied in anti-CD20–mediated tumor control, and adaptive immunity has long been underestimated. The purpose of this study was to explore whether T cells are involved in mediating the effects of anti-CD20 therapy and what factors contribute to adaptive immune response–related resistance. Experimental Design: Using a syngeneic mouse B-cell lymphoma model, we investigated the role of CD8+ T cells in anti-CD20–mediated tumor regression. Furthermore, we revealed how the tumor-specific T-cell response was initiated by anti-CD20. Finally, we studied adaptive immune response–related resistance in advanced B-cell lymphoma. Results: CD8+ T cells played an essential role in anti-CD20–mediated tumor regression. Mechanistically, anti-CD20 therapy promoted dendritic cell (DC)-mediated cross-presentation. Importantly, macrophages were also necessary for the increase in the tumor-specific CTL response after anti-CD20 treatment, via the production of type I IFN to activate DC function. Furthermore, adaptive resistance is gradually developed through the CTLA-4 pathway in Treg cells in larger lymphomas. Further blockade of CTLA-4 can synergize with anti-CD20 treatment in antitumor activities. Conclusions: The therapeutic function of anti-CD20 depends on tumor-specific CD8+ T-cell responses initiated by anti-CD20 through macrophages and DCs. CTLA-4 blockade can synergize with anti-CD20 to overcome adaptive immune response–related resistance in advanced B-cell lymphoma. Clin Cancer Res; 23(1); 193–203. ©2016 AACR.
Supplementary Figure S6 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Jason Bugno,Liangliang Wang,Xianbin Yu,Xuezhi Cao,Jiaai Wang,Xiaona Huang,Kaiting Yang,Andras Piffko,Katherine Chen,Stephen Y. Luo,Emile Naccasha,Yuzhu Hou,Sherry Fu,Chuan He,Yang-xin Fu,Hua L. Liang,Ralph R. Weichselbaum

DOI: https://doi.org/10.1158/1078-0432.27142126

2024-01-01

Abstract:Supplementary Figure S6. Treg tumor infiltration after local RT in MC38 tumors and splenic cDC isolation strategy.
Supplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22758761.v1

2023-01-01

Abstract:Supplementary Fig. S8 shows CD8 T cell-dependent control of tumors containing a B2m-/- population with inactivated Rnf31 and Atg5 genes.
Supplementary Figure S6 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy

Yazi Yang,Sen Qin,Mengyu Yang,Ting Wang,Ru Feng,Chunli Zhang,Enrun Zheng,Qinghua Li,Pengyu Xiang,Shangyong Ning,Xiaodong Xu,Xin Zuo,Shuai Zhang,Xiaoya Yun,Xuehong Zhou,Yue Wang,Lin He,Yongfeng Shang,Luyang Sun,Hui Liu

DOI: https://doi.org/10.1158/1078-0432.27013657.v1

2024-01-01

Abstract:Supplementary Figure S6. BCMA CAR-T Therapy Enhances the Proportion and Cytotoxic Activity of CD8+ Effector T Cells, Positively Correlating with Therapeutic Responsivity.
Supplementary Figure 6 from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells Against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

Yongxian Hu,Zhao Wu,Yi Luo,Jimin Shi,Jian Yu,Chengfei Pu,Zuyu Liang,Guoqing Wei,Qu Cui,Jie Sun,Jing Jiang,Jue Xie,Yamin Tan,Wanmao Ni,Jifang Tu,Jinping Wang,Aiyun Jin,Hao Zhang,Zhen Cai,Lei Xiao,He Huang

DOI: https://doi.org/10.1158/1078-0432.22462346.v1

2023-01-01

Abstract:The cumulative incidence of non-relapse mortality are shown.
Supplementary Figure 5 from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression

Shinan Li,Rui Sun,Yongyan Chen,Wei H,Zhigang Tian

DOI: https://doi.org/10.1158/0008-5472.22407831.v1

2023-01-01

Abstract:S. Fig. 5. IL-18 silencing inhibits MDSC accumulation and restores T cell function.
Supplemental Figure S3 from Cytokine-like Molecule CCDC134 Contributes to CD8<sup>+</sup> T-cell Effector Functions in Cancer Immunotherapy

Lin Xiao

DOI: https://doi.org/10.1158/0008-5472.22402079

2023-01-01

Abstract:Identification of established CCDC134 transgenic mice.
Supplementary Figure S9 from CD24hiCD27+ Bregs Within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer

Huanhuan Huang,Yao,Lesang Shen,Jingxin Jiang,Ting Zhang,Jia Xiong,Jiaxin Li,Shanshan Sun,Siwei Zheng,Fang Jia,Jun Zhou,Xiuyan Yu,Wuzhen Chen,Jun Shen,Wenjie Xia,Xuan Shao,Qingqing Wang,Jian Huang,Chao Ni

DOI: https://doi.org/10.1158/1078-0432.24826134.v1

2023-01-01

Abstract:Fig. S9. CD24hiCD27+ Bregs are the main cellular sources of IL-10, IL-6 and TNF-α among CD45+ immune cells within the mLNs.
Supplementary Figure S5 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy

Yazi Yang,Sen Qin,Mengyu Yang,Ting Wang,Ru Feng,Chunli Zhang,Enrun Zheng,Qinghua Li,Pengyu Xiang,Shangyong Ning,Xiaodong Xu,Xin Zuo,Shuai Zhang,Xiaoya Yun,Xuehong Zhou,Yue Wang,Lin He,Yongfeng Shang,Luyang Sun,Hui Liu

DOI: https://doi.org/10.1158/1078-0432.27013660

2024-01-01

Abstract:Supplementary Figure S5. BCMA CAR-T Therapy Enhances the Proportion and Cytotoxic Activity of CD8+ Effector T Cells, Positively Correlating with Therapeutic Responsivity.
Supplementary Figure S4 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Jason Bugno,Liangliang Wang,Xianbin Yu,Xuezhi Cao,Jiaai Wang,Xiaona Huang,Kaiting Yang,Andras Piffko,Katherine Chen,Stephen Y. Luo,Emile Naccasha,Yuzhu Hou,Sherry Fu,Chuan He,Yang-xin Fu,Hua L. Liang,Ralph R. Weichselbaum

DOI: https://doi.org/10.1158/1078-0432.27142132

2024-01-01

Abstract:Supplementary Figure S4. Human expression of FOXP3 with RT and correlation with a Human DC_Ccl22 Homolog Score among TCGA cohorts
Supplementary Figure 7 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xing,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xiaoze Du,Tang Li,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399932.v1

2023-01-01

Abstract:PDF file - 78KB, Supplementary Figure 7 Confirmation of LAG-3 expression on T cells.
Supplementary Figure 9 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver versus Lung Metastases

Jian Ye,Weihua Guo,Chongkai Wang,Colt A. Egelston,Massimo D'Apuzzo,Geereesh Shankar,Marwan G. Fakih,Peter P. Lee

DOI: https://doi.org/10.1158/2767-9764.24298823

2023-01-01

Abstract:Progressive maturation of TLS in CRC primary tumor.
Supplementary Figure 4 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma

Jing Shi,Qiang Gao,Zhichao Wang,Jing Zhou,Xiaoying Wang,Zhihui Min,Ying‐Hong Shi,Guo–Ming Shi,Zhen‐Bin Ding,Ai–Wu Ke,Zhi Dai,Shuang–Jian Qiu,Kun Song,Jia Fan

DOI: https://doi.org/10.1158/1078-0432.22450295

2023-01-01

Abstract:PDF file - 498K, Representative flow cytometry data showing that percentages of granzyme B+ and TRAIL+ cells in total CD20+ cells are significantly higher in MIL-Bs than in PIL-Bs, respectively (n=5).
Supplemental Figure S5 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402073

2023-01-01

Abstract:Involvement of CD4+ T cells in the induction of antitumor activity by CCDC134.

Supplemental Figure 6 from CTLA-4 Limits Anti-CD20–Mediated Tumor Regression

Supplemental Figure 1 from CTLA-4 Limits Anti-CD20–Mediated Tumor Regression

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

CTLA-4 Limits Anti-Cd20-mediated Tumor Regression

Supplementary Figure S6 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines

Supplementary Figure S6 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy

Supplementary Figure 6 from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells Against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

Supplementary Figure 5 from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression

Supplemental Figure S3 from Cytokine-like Molecule CCDC134 Contributes to CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Effector Functions in Cancer Immunotherapy

Supplementary Figure S9 from CD24hiCD27+ Bregs Within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer

Supplementary Figure S5 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy

Supplementary Figure S4 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Figure 7 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Figure 9 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver versus Lung Metastases

Supplementary Figure 4 from Margin-Infiltrating CD20&lt;sup&gt;+&lt;/sup&gt; B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma

Supplemental Figure S5 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Supplemental Figure S3 from Cytokine-like Molecule CCDC134 Contributes to CD8<sup>+</sup> T-cell Effector Functions in Cancer Immunotherapy

Supplementary Figure 4 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma